Chemistry:5-MBPB
5-MBPB (also known as 5-MPBP and 5-MABB) is an amphetamine and phenylisobutylamine derivative which is structurally related to MDMA and has been sold as a designer drug. It can be described as the benzofuran-5-yl analogue of MBDB or the butanamine homologue of 5-MAPB, and is also a structural isomer of 5-EAPB and 6-EAPB. Anecdotal reports suggest this compound has been sold as a designer drug in various European countries since early 2015, but the first definitive identification was made in December 2015 by a forensic laboratory in Slovenia.[1]
5-MBPB is similar in structure to compounds such as 5-APB which are claimed to be agonists of the 5-HT2C receptor.[2]
5-MBPB (5-MABB) has been found to act as a potent serotonin–norepinephrine–dopamine releasing agent (SNDRA), with preference for induction of serotonin release over norepinephrine and dopamine release, and fully substitutes for MDMA in animal drug discrimination tests.[3] Unlike 5-MAPB, it is a relatively weak serotonin 5-HT1B receptor agonist.[4]
See also
- Substituted benzofuran
- 6-MBPB (6-MABB)
References
- ↑ European Monitoring Center for Drugs and Drug Addiction – Europol 2015 Annual Report on the implementation of Council Decision 2005/387/JHA
- ↑ Karin Briner et al, "Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists", US patent 7045545, published 2000-01-19, issued 2006-16-03
- ↑ "Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine". J Pharmacol Exp Ther 391 (1): 22–29. September 2024. doi:10.1124/jpet.123.001837. PMID 38272669.
- ↑ Matthew Baggott, "Advantageous benzofuran compositions for mental disorders or enhancement", US patent 20230150963, published 2023 May 18, assigned to Tactogen
External links
 |  |
